Post-approval studies (Phase 4)Study completedNCT00639691
What this trial is testing
A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy
Who this might be right for
Asthma
Novartis 48